My Take: This is a pretty modest pop for TRMB. Plus, the stock is currently in a pronounced downtrend, and I doubt this catalyst will be enough to change its short-term trajectory.
Bionomics [BNOX] - Last Close: $0.9850
Bionomics is skyrocketing after a clinical update.
This morning, the tiny biotech firm said a Phase 2b ATTUNE trial of BNC210 for PTSD achieved its primary endpoint.
Bionomics said the study resulted in "statistically significant" improvements in PTSD symptoms from baseline to week 12.
The drug also met its two secondary endpoints by producing improvements in depressive symptoms and sleep conditions.
In light of the study's findings, Bionomics said it's planning to advance BNC210 into registrational studies.
This news catapulted shares of BNOX to enormous gains. Shares are currently up 561.1% on active trading volume.
My Take: Woah, this is an outrageous rally. It could be the result of a targeted campaign designed to capitalize on the stock's tiny float. Either way, I expect a pullback at some point.
Gritstone Bio [GRTS] - Last Close: $1.19
Gritstone Bio just landed a major contract.
Late Wednesday, the tiny biotech said it was awarded a contract to conduct a Phase 2b comparative trial for its mRNA COVID-19 vaccine candidate.
The contract was awarded by the Biomedical Advanced Research and Development Authority, and it's valued at up to $433 million.
Gritstone said it will conduct a 10,000 participant trial to compare its vaccine candidate with an approved COVID-19 vaccine.
GRTS is up 28.5% on the news.
My Take: GRTS has a pretty ugly chart, but this sounds like it could be a game-changing deal for the company. I'm not jumping in just yet, but it's on my radar as a potential long-short biotech play.
Baudax Bio [BXRX] - Last Close: $0.30
A key regulatory ruling is boosting shares of Baudax Bio.
The tiny biotech announced this morning that the FDA had granted an orphan drug designation for its lead clinical candidate, TI-168.
TI-168 is the company’s FVIII-specific therapy designed to reliably and effectively treat Hemophilia A patients with FVIII inhibitors.
Baudax Bio Pres. & CEO Gerri Henwood said the decision "highlights the urgent need for innovation and new therapeutic options for Hemophilia A patients.”
Henwood also said the company believes it can activate a Phase 1/2a clinical trial and advance the therapy to further clinical trials by early 2024.
BXRX is up 77.4% in response to the announcement.
My Take: BXRX is in a similar situation as BNOX, but this rally seems a lot more grounded. Either way, this tiny float stock has a long road ahead of it, and now might not be the right time to throw your hat in the ring. '
